Share This

PR Newswire Asia's news > Health Care/Hospital

 |   Title only   |   Print    Next page > 
     
ONCOCLÍNICAS APPROVES R$ 1.5 BILLION CAPITAL INCREASE
Operation aims to strengthen the Company's financial position and maintain growth strategy ...
2024-05-24T    Banking/Financial Service   Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Cure Genetics Announced Promising Safety and Efficacy Data of CAR-NKT Product CGC729 for RCC at ASGCT 2024
SUZHOU, China , May 23, 2024 /PRNewswire/ -- On May 10, 2024 , Cure Genetics announced the safety and efficacy data of their CAR-NKT product, CGC729, for patients with relapsed and refractory ...
2024-05-23T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Providence and Ontario Institute for Cancer Research (OICR) partnering to discover and develop mRNA therapeutics
CALGARY, AB and TORONTO , May 23, 2024 /PRNewswire/ -- Providence Therapeutic Holdings Inc. (" Providence "), a messenger RNA (mRNA) and lipid nanoparticle platform company engaged in the ...
2024-05-23T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Vatech Partners with Tygerberg Public Hospital to Improve Dental Care in South Africa
SEOUL, South Korea , May 23, 2024 /PRNewswire/ -- Vatech, a global leader in the dental imaging market, is launching a project to improve dental healthcare in South Africa . Vatech announced today ...
2024-05-23T    Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
Complete Genomics opens U.S. supply chain to genomic sequencing customers through a new manufacturing facility at its San Jose, Calif. headquarters
SAN JOSE, Calif. , May 23, 2024 /PRNewswire/ -- Complete Genomics, a pioneering genomic sequencing company, recently welcomed vendors, suppliers, customers and employees to a May 17 grand opening ...
2024-05-23T    Biotechnology   Computer/Electronics   Health Care/Hospital   Transportation 
Laekna Announces FDA Approval for the Phase III Clinical Trial Protocol of LAE002 (Afuresertib) PLUS LAE001 for the Treatment of Prostate Cancer
SHANGHAI and WARREN, N.J. , May 23, 2024 /PRNewswire/ -- Laekna, Inc. (2105.HK), a science-driven, clinical-stage biotechnology company, announced that the company has received approval ...
2024-05-23T    Health Care/Hospital   Medical/Pharmaceuticals 
Guo Guangchang: Fosun Steadfastly Focuses on Innovation + Globalization
HONG KONG , May 23, 2024 /PRNewswire/ -- The 4th BEYOND International Technology Innovation Expo (BEYOND Expo 2024) commenced with a spectacular opening ceremony on 22 May at the Venetian Theatre in ...
2024-05-23T    Banking/Financial Service   Health Care/Hospital   Medical/Pharmaceuticals 
New report from Access to Medicine Foundation shows what pharma companies can do to ensure the few promising antimicrobials in development reach patients on the frontlines of drug resistance
AMSTERDAM , May 23, 2024 /PRNewswire/ -- The race to create replacement antibiotics and antifungals to combat superbugs is falling dangerously short, putting people across the world at risk. However, ...
2024-05-23T    Health Care/Hospital   Medical/Pharmaceuticals 
111, Inc. Announces First Quarter 2024 Unaudited Financial Results
Turned to Quarterly Operational Profitability for the First Time Operating Expenses as a Percentage of Revenues Decreased 120 Basis Points YoY to 5.8% Achieved Positive Operating Cash Flow ...
2024-05-23T    Computer/Electronics   Health Care/Hospital   Medical/Pharmaceuticals 
Manulife Launches a Two-Year Strategic Charity Partnership with Mind HK
Key initiatives aim to address misconceptions towards mental health and  empower sustained health and well-being                           ...
2024-05-23T    Banking/Financial Service   Health Care/Hospital   Insurance 
  Next page >

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.